183 related articles for article (PubMed ID: 15126331)
1. Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer.
Narayan G; Arias-Pulido H; Nandula SV; Basso K; Sugirtharaj DD; Vargas H; Mansukhani M; Villella J; Meyer L; Schneider A; Gissmann L; Dürst M; Pothuri B; Murty VV
Cancer Res; 2004 May; 64(9):2994-7. PubMed ID: 15126331
[TBL] [Abstract][Full Text] [Related]
2. Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway.
Wang Z; Li M; Lu S; Zhang Y; Wang H
Cancer Biol Ther; 2006 Mar; 5(3):256-60. PubMed ID: 16418574
[TBL] [Abstract][Full Text] [Related]
3. Function of the Fanconi anemia pathway in Fanconi anemia complementation group F and D1 cells.
Siddique MA; Nakanishi K; Taniguchi T; Grompe M; D'Andrea AD
Exp Hematol; 2001 Dec; 29(12):1448-55. PubMed ID: 11750104
[TBL] [Abstract][Full Text] [Related]
4. The Fanconi Anemia/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers.
D'Andrea AD
Cell Cycle; 2003; 2(4):290-2. PubMed ID: 12851475
[TBL] [Abstract][Full Text] [Related]
5. The Fanconi anemia pathway sensitizes to DNA alkylating agents by inducing JNK-p53-dependent mitochondrial apoptosis in breast cancer cells.
Zhao L; Li Y; He M; Song Z; Lin S; Yu Z; Bai X; Wang E; Wei M
Int J Oncol; 2014 Jul; 45(1):129-38. PubMed ID: 24789349
[TBL] [Abstract][Full Text] [Related]
6. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors.
Taniguchi T; Tischkowitz M; Ameziane N; Hodgson SV; Mathew CG; Joenje H; Mok SC; D'Andrea AD
Nat Med; 2003 May; 9(5):568-74. PubMed ID: 12692539
[TBL] [Abstract][Full Text] [Related]
7. Bi-allelic silencing of the Fanconi anaemia gene FANCF in acute myeloid leukaemia.
Tischkowitz M; Ameziane N; Waisfisz Q; De Winter JP; Harris R; Taniguchi T; D'Andrea A; Hodgson SV; Mathew CG; Joenje H
Br J Haematol; 2003 Nov; 123(3):469-71. PubMed ID: 14617007
[TBL] [Abstract][Full Text] [Related]
8. The Fanconi anemia protein FANCF forms a nuclear complex with FANCA, FANCC and FANCG.
de Winter JP; van der Weel L; de Groot J; Stone S; Waisfisz Q; Arwert F; Scheper RJ; Kruyt FA; Hoatlin ME; Joenje H
Hum Mol Genet; 2000 Nov; 9(18):2665-74. PubMed ID: 11063725
[TBL] [Abstract][Full Text] [Related]
9. Promoter hypermethylation-mediated inactivation of multiple Slit-Robo pathway genes in cervical cancer progression.
Narayan G; Goparaju C; Arias-Pulido H; Kaufmann AM; Schneider A; Dürst M; Mansukhani M; Pothuri B; Murty VV
Mol Cancer; 2006 May; 5():16. PubMed ID: 16700909
[TBL] [Abstract][Full Text] [Related]
10. Hypermethylation of the FANCC and FANCL promoter regions in sporadic acute leukaemia.
Hess CJ; Ameziane N; Schuurhuis GJ; Errami A; Denkers F; Kaspers GJ; Cloos J; Joenje H; Reinhardt D; Ossenkoppele GJ; Zwaan CM; Waisfisz Q
Cell Oncol; 2008; 30(4):299-306. PubMed ID: 18607065
[TBL] [Abstract][Full Text] [Related]
11. Disruption of the FA/BRCA pathway in bladder cancer.
Neveling K; Kalb R; Florl AR; Herterich S; Friedl R; Hoehn H; Hader C; Hartmann FH; Nanda I; Steinlein C; Schmid M; Tonnies H; Hurst CD; Knowles MA; Hanenberg H; Schulz WA; Schindler D
Cytogenet Genome Res; 2007; 118(2-4):166-76. PubMed ID: 18000367
[TBL] [Abstract][Full Text] [Related]
12. Variation in cisplatinum sensitivity is not associated with Fanconi Anemia/BRCA pathway inactivation in head and neck squamous cell carcinoma cell lines.
Snyder ER; Ricker JL; Chen Z; Waes CV
Cancer Lett; 2007 Jan; 245(1-2):75-80. PubMed ID: 16466850
[TBL] [Abstract][Full Text] [Related]
13. Current knowledge on the pathophysiology of Fanconi anemia: from genes to phenotypes.
Yamashita T; Nakahata T
Int J Hematol; 2001 Jul; 74(1):33-41. PubMed ID: 11530803
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneous activation of the Fanconi anemia pathway by patient-derived FANCA mutants.
Adachi D; Oda T; Yagasaki H; Nakasato K; Taniguchi T; D'Andrea AD; Asano S; Yamashita T
Hum Mol Genet; 2002 Dec; 11(25):3125-34. PubMed ID: 12444097
[TBL] [Abstract][Full Text] [Related]
15. Gene silencing of FANCF potentiates the sensitivity to mitoxantrone through activation of JNK and p38 signal pathways in breast cancer cells.
Li Y; Zhao L; Sun H; Yu J; Li N; Liang J; Wang Y; He M; Bai X; Yu Z; Zheng Z; Mi X; Wang E; Wei M
PLoS One; 2012; 7(8):e44254. PubMed ID: 22952942
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival.
Marsit CJ; Liu M; Nelson HH; Posner M; Suzuki M; Kelsey KT
Oncogene; 2004 Jan; 23(4):1000-4. PubMed ID: 14647419
[TBL] [Abstract][Full Text] [Related]
17. RNA interference-mediated FANCF silencing sensitizes OVCAR3 ovarian cancer cells to adriamycin through increased adriamycin-induced apoptosis dependent on JNK activation.
He M; Sun HG; Hao JY; Li YL; Yu JK; Yan YY; Zhao L; Li N; Wang Y; Bai XF; Yu ZJ; Zheng ZH; Mi XY; Wang EH; Wei MJ
Oncol Rep; 2013 May; 29(5):1721-9. PubMed ID: 23440494
[TBL] [Abstract][Full Text] [Related]
18. FANCF methylation contributes to chemoselectivity in ovarian cancer.
Olopade OI; Wei M
Cancer Cell; 2003 May; 3(5):417-20. PubMed ID: 12781358
[TBL] [Abstract][Full Text] [Related]
19. Loss of heterozygosity in FANCG, FANCF and BRIP1 from head and neck squamous cell carcinoma of the oral cavity.
Türke C; Horn S; Petto C; Labudde D; Lauer G; Wittenburg G
Int J Oncol; 2017 Jun; 50(6):2207-2220. PubMed ID: 28440438
[TBL] [Abstract][Full Text] [Related]
20. Altered expression of FANCL confers mitomycin C sensitivity in Calu-6 lung cancer cells.
Zhang J; Wang X; Lin CJ; Couch FJ; Fei P
Cancer Biol Ther; 2006 Dec; 5(12):1632-6. PubMed ID: 17106252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
